Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2009. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility under the Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction notifications.
Material Changes
No material financial changes versus prior periods are reported in this filing. The only reported activity is the increase in share interests by specific individuals following a dividend reinvestment.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items. It strictly details the reinvestment of dividends paid on October 8, 2009, into Ordinary shares purchased on October 14, 2009, at a price of £12.65 per share.
Important Facts for Investors
- Transaction Type: Notification of increased share interests by directors via dividend reinvestment.
- Share Price: £12.65 per share.
- Transaction Date: October 14, 2009.
- Dividend Date: October 8, 2009.
- Individuals Involved: Dr M M Slaoui (262 shares), Mr M Dunoyer (126 shares), and Dr D Pulman (193 shares).
- Financial Data: No financial performance metrics are included in this specific filing.